Champions Oncology (CSBR)

Its business is centred on two complementary activities. Through its clinical-facing personalized oncology services, Champions Oncology supports physicians and patients by testing tumor samples against drug panels and producing information that can help inform treatment decisions. Through its translational oncology services, which represent the core revenue driver, the company provides pharmaceutical and biotechnology customers with preclinical research tools used to evaluate oncology drug candidates before and during clinical development.

A key feature of Champions Oncology is its tumor model platform, including patient-derived xenograft models that are designed to preserve characteristics of human cancers in research settings. These models can be used to study tumor biology, compare drug combinations, identify biomarkers, and assess potential efficacy across different cancer types.

The company operates in a specialised market where demand is linked to oncology research spending and the pharmaceutical industry’s need for more predictive preclinical data. Rather than developing its own cancer drugs, Champions Oncology primarily enables other organisations to make better development decisions. Its value proposition rests on high-quality tumor data, scientific expertise, and the ability to provide research services that connect laboratory findings with real-world cancer treatment challenges.